<DOC>
	<DOCNO>NCT01445197</DOCNO>
	<brief_summary>This clinical study investigate well Biostate work treatment male patient age 12 year clot factor deficiency aggravate development antibody . The antibody direct clot factor give replacement therapy usually make therapy unsuccessful . The treatment use study call immune tolerance therapy .</brief_summary>
	<brief_title>Study Biostate Treatment Children With Hemophilia A Complicated Antibody Development</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject diagnose haemophilia A ( ≤ 2 % FVIII level absence factor replacement , accord medical history ) . Age 28 day &lt; 12 year . Subject eligible immune tolerance induction ( ITI ) therapy The subject receive ITI previously . Subjects historical peak inhibitor titre ≥ 200 BU/mL . Concomitant treatment drug immunosuppressive side effect ( eg , systemic corticosteroid ) , azathioprine , cyclophosphamide , high dose immunoglobulin use protein A column plasmapheresis interferon . High risk cardiovascular , cerebrovascular , thromboembolic event ( exclude catheter thrombosis ) judge investigator . Subjects human immunodeficiency virus ( HIV ) 1 HIV2 positive ( report medical record determine screen ) .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>